In pharmaceutical and biotech manufacturing, Quality Assurance (QA) is more than a department, it is a culture of demonstrable reliability that runs through every phase of product development, manufacturing, and distribution. From the earliest stages of development through to commercial release, GMP compliance is not optional; it is an absolute requirement. SIRE Life Sciences connects Dutch life sciences organizations with the QA professionals they need to meet that standard consistently.
Growing demand for QA talent in the Netherlands
The Netherlands ranks among the top five pharmaceutical manufacturing countries in Europe. With international players such as MSD, Janssen, Organon, and Astellas, alongside a growing cluster of biotech companies in Leiden, Utrecht, Amsterdam, and Eindhoven, demand for qualified QA professionals has risen sharply in recent years. At the same time, the supply of experienced QA specialists remains tight, since the combination of technical depth, regulatory knowledge, and operational insight is genuinely rare.
The QA profiles SIRE Life Sciences places
The QA landscape in the pharmaceutical industry is broad and varied. At the senior level, this includes Qualified Persons (QP) responsible for batch release under EU GMP Annex 16, Responsible Persons (RP) for GDP-certified distribution, QA Directors and Head of Quality for leadership roles, and interim Quality Management System (QMS) managers for organizations in transition or growth. This overlaps closely with the career paths we outlined in our earlier post on Quality Assurance in life sciences: career paths, responsibilities, and salary benchmarks.
At the operational level, our consultants work as QA Specialists and QA Engineers handling document management, deviation management, and CAPA processes, as QA Auditors for internal and supplier audits, as QA Analysts for trend analysis and quality data, and as Document Control Specialists for GMP documentation and change control.
GMP compliance in a shifting regulatory landscape
European GMP regulation has changed substantially in recent years. The revised Annex 1 for sterile manufacturing, tightened data integrity requirements under ALCOA+, increasing EMA attention on pharmacovigilance, and the rollout of IDMP/xEVMPD for medicine registrations are all placing new demands on QA organizations. Companies that cannot scale QA capacity quickly enough risk inspection findings, production delays, and in the worst case, batch recalls. This is closely tied to the compliance distinctions we explored in GCP vs. GDP in life sciences.
SIRE Life Sciences helps organizations mitigate this risk by supplying QA experts who are ready to contribute from day one, with a solid grasp of Dutch and European regulation and no lengthy onboarding curve.
The Qualified Person: scarce and strategic
One of the most sought-after profiles in Dutch pharma is the Qualified Person (QP). A QP is legally responsible for releasing every production batch and must personally certify that a product meets all GMP requirements, its Marketing Authorisation, and applicable legislation. Finding an available, experienced QP, particularly on an interim basis, is a major challenge for many organizations. SIRE Life Sciences maintains a dedicated network of certified QPs and Responsible Persons across the Netherlands and Belgium, available for both short-term assignments and longer-term placements.
Working with SIRE Life Sciences on QA challenges
SIRE Life Sciences offers more than recruitment or secondment. As a strategic consultancy partner, we help think through your broader QA organization: which profiles you need now, which competencies may be missing in the medium term, and how to build a resilient quality organization ready for the next inspection cycle. Our AI-driven matching identifies the right QA consultant for your specific context, taking into account sector experience, regulatory framework, and organizational culture.
This article originally appeared on the SIRE Life Sciences blog.
Top comments (0)